<!-- Google Tag Manager -->
<!-- ADDED ON 05/01/2023 -->
<!-- All services and snippets (AKA tags) have been removed from this file -->
<!-- They are handled in the ralated container in Google Tag Manger -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-TR2CDD');</script>
<!-- End Google Tag Manager -->
<html lang="en-US">
<head>
<title>RFA-DA-25-048: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)</title>
<meta content="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) RFA-DA-25-048. NIDA" name="description"/>
<meta content="RFA-DA-25-048: Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)" name="Keywords"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../guide_styles/css/bootstrap.min.css" rel="stylesheet"/>
<link href="../guide_styles/css/style.css" rel="stylesheet"/>
</head>
<body>
<div class="container">
<div class="row">
<div class="col-xs-12">
<body onload="initContent()">
<div class="container">
<div class="row">
<div class="heading1" id="page-title" tabindex="0">Department of Health and Human Services</div>
<div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165166" data-element-required="false" data-element-type="TEXT" data-section-code="OI">
<a name="_Part_1._Overview"></a><h1 class="heading1">Part 1. Overview Information</h1>
</div>
<div class="row" data-index="2">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165167" data-element-required="true" data-element-type="TEXT" data-section-code="OI" tabindex="0">
					Participating Organization(s) 
			</div>
<div class="col-md-8 datacolumn">
<p>National Institutes of Health (<a href="http://www.nih.gov">NIH</a>)</p>
</div>
</div>
<div class="row" data-index="3">
<div class="col-md-push-4 col-md-8 datacolumn">
</div>
</div>
<div class="row" data-index="4">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165169" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Components of Participating Organizations 
			</div>
<div class="col-md-8 datacolumn">
<p>National Institute on Drug Abuse (<a href="https://www.drugabuse.gov/" rel="noreferrer" target="_blank">NIDA</a>) 
		</p></div>
</div>
<div class="row" data-index="5">
<div class="col-md-push-4 col-md-8 datacolumn">
</div>
</div>
<div class="row" data-index="6">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165171" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Funding Opportunity Title 
			</div>
<div class="col-md-8 datacolumn">
<span class="title">Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)</span>
</div>
</div>
<div class="row" data-index="7">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165172" data-element-required="true" data-element-type="TEXT" data-section-code="OI" tabindex="0">
					Activity Code 
			</div>
<div class="col-md-8 datacolumn">
<p><a href="//grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r43&amp;Search.x=16&amp;Search.y=10&amp;Search_Type=Activity">R43</a>/<a href="//grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=r44&amp;Search.x=0&amp;Search.y=0&amp;Search_Type=Activity">R44</a> Small Business Innovation Research (SBIR) Grant - Phase I, Phase II, and Fast-Track</p>
</div>
</div>
<div class="row" data-index="8">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165173" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Announcement Type 
			</div>
<div class="col-md-8 datacolumn">
                New 
		</div>
</div>
<div class="row" data-index="9">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165174" data-element-required="true" data-element-type="TEXT" data-section-code="OI" tabindex="0">
					Related Notices</div><div class="col-md-8 datacolumn">
<ul>
<li><strong>February 21, 2024</strong> - Notice of Change to the budget limits in RFA-DA-25-047 and RFA-DA-25-048, "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 and R43/R44 Clinical Trials Optional)". See Notice <a href="//grants.nih.gov/grants/guide/notice-files/NOT-DA-23-067.html">NOT-DA-23-067</a></li>
<li><strong>December 13, 2023</strong> - Notice of Change to the budget limits in RFA-DA-25-047 and RFA-DA-25-048, "Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 and R43/R44 Clinical Trials Optional)". See Notice <a href="//grants.nih.gov/grants/guide/notice-files/NOT-DA-23-047.html">NOT-DA-23-047</a></li>
<li>
<strong>November 14, 2023</strong> - Clarification of Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements. See Notice <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-029.html">NOT-OD-24-029</a>
</li>
<li class="Normal"><strong>June 12, 2023</strong>- Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements  . See <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-139.html">NOT-OD-23-139</a>.</li>
<li class="Normal"><strong>February 23, 2023</strong>- Notice of Change to Minimum Performance Standards for SBIR and STTR Applicants  . See <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-092.html">NOT-OD-23-092</a>.</li>
<li class="Normal"><strong>August 31, 2022</strong>- Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice <a href="https://grants.nih.gov/grants/guide/notice-files/not-od-22-198.html">NOT-OD-22-198</a>.</li>
<li class="Normal"><strong>August 5, 2022</strong>- Implementation Details for the NIH Data Management and Sharing Policy. See Notice <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-189.html">NOT-OD-22-189</a>.</li>
</ul>
</div>
</div>
<div class="row" data-index="10">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165175" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Funding Opportunity Number (FON) 
			</div>
<div class="col-md-8 datacolumn">
<span class="noticenum">RFA-DA-25-048</span>
</div>
</div>
<div class="row" data-index="11">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165176" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Companion Funding Opportunity 
			</div>
<div class="col-md-8 datacolumn">
<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html" rel="noreferrer" target="_blank">RFA-DA-25-047</a>
<span class="separator" style="position:relative;left:-3px">,</span>
<a href="https://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=R41&amp;&amp;Search.x=0&amp;&amp;Search.y=0&amp;&amp;Search_Type=Activity" rel="noreferrer" target="_blank">R41</a>/
			<a href="https://grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=R42&amp;&amp;Search.x=0&amp;&amp;Search.y=0&amp;&amp;Search_Type=Activity" rel="noreferrer" target="_blank">R42</a>
   Small Business Technology Transfer (STTR) Grants - Phase I/ * Small Business Technology Transfer (STTR) Grants - Phase II
    
	
	<br/>
</div>
</div>
<div class="row" data-index="12">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165177" data-element-required="true" data-element-type="TEXT" data-section-code="OI" tabindex="0">
					Number of Applications 
			</div>
<div class="col-md-8 datacolumn">
<p>See <a href="#_3._Additional_Information">Section III. 3. Additional Information on Eligibility</a>.</p>
</div>
</div>
<div class="row" data-index="13">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165178" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI" tabindex="0">
					Assistance Listing Number 
			</div>
<div class="col-md-8 datacolumn">
                93.279 
		</div>
</div>
<div class="row" data-index="14">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165179" data-element-required="true" data-element-type="TEXT" data-section-code="OI" tabindex="0">
					Notice of Funding Opportunity Purpose 
			</div>
<div class="col-md-8 datacolumn">
<p>The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder</p>
</div>
</div>
<!--This variable defines that we need to start a new row. -->
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165180" data-element-required="true" data-element-type="TEXT" data-section-code="KD">
<a name="_Key_Dates"></a><h2 class="heading2">Key Dates</h2>
</div>
<div class="row" data-index="16">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165181" data-element-required="true" data-element-type="DATE" data-section-code="KD" tabindex="0">
					Posted Date 
			</div>
<div class="col-md-8 datacolumn">
                September 28, 2023 
		</div>
</div>
<div class="row" data-index="17">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165182" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="KD" tabindex="0">
					Open Date (Earliest Submission Date) 
			</div>
<div class="col-md-8 datacolumn">
                February 13, 2024 
		</div>
</div>
<div class="row" data-index="18">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165183" data-element-required="true" data-element-type="TEXT" data-section-code="KD" tabindex="0">
					Letter of Intent Due Date(s) 
			</div>
<div class="col-md-8 datacolumn">
<p>30 days prior to application due date </p>
</div>
</div>
<!--This variable defines that we need to start a new row. -->
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165184" data-element-required="false" data-element-type="LINKED_ELEMENT" data-section-code="KD">
<table class="table table-bordered table-striped table-hover eraDataTable" id="keyDatesContentTable">
<thead>
<tr>
<th class="text-center" colspan="3" scope="col" style="border:2px solid #bcbcbc;">Application Due Dates</th>
<th class="text-center" colspan="3" scope="col" style="border:2px solid #bcbcbc;">Review and Award Cycles</th>
</tr>
<tr>
<th class="text-center" scope="col" style="width:16.66%;border-left:2px solid #bcbcbc;">New</th>
<th class="text-center" scope="col" style="width:16.66%">Renewal / Resubmission / Revision (as allowed)</th>
<th class="text-center" scope="col" style="width:16.66%;border-right:2px solid #bcbcbc;">AIDS - New/Renewal/Resubmission/Revision, as allowed</th>
<th class="text-center" scope="col" style="width:16.66%">Scientific Merit Review</th>
<th class="text-center" scope="col" style="width:16.66%">Advisory Council Review</th>
<th class="text-center" scope="col" style="width:16.66%;border-right:2px solid #bcbcbc;">Earliest Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>
							March 13, 2024 
					</td>
<td>
							Not Applicable
					</td>
<td>
							Not Applicable
					</td>
<td>July 2024</td>
<td>							October 2024

					</td>
<td>December 2024</td>
</tr>
<tr>
<td>
							March 13, 2025 
					</td>
<td>
							March 13, 2025
					</td>
<td>
							Not Applicable
					</td>
<td>July 2025</td>
<td>							October 2025

					</td>
<td>December 2025</td>
</tr>
<tr>
<td>
							March 13, 2026 
					</td>
<td>
							March 13, 2026
					</td>
<td>
							Not Applicable
					</td>
<td>July 2026</td>
<td>							October 2026

					</td>
<td>December 2026</td>
</tr>
</tbody>
</table>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165185" data-element-required="false" data-element-type="TEXT" data-section-code="KD">
</div>
<div class="row" data-index="21">
<div class="col-md-push-4 col-md-8 datacolumn">
<p class="Normal">All applications are due by 5:00 PM local time of applicant organization. </p>
<p class="Normal">Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.</p>
</div>
</div>
<!--This variable defines that we need to start a new row. -->
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165187" data-element-required="false" data-element-type="TEXT" data-section-code="KD">
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165188" data-element-required="false" data-element-type="TEXT" data-section-code="KD">
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165189" data-element-required="false" data-element-type="TEXT" data-section-code="KD">
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165190" data-element-required="false" data-element-type="TEXT" data-section-code="KD">
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165191" data-element-required="false" data-element-type="CHECKBOX" data-section-code="KD">
</div>
<div class="row" data-index="27">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165192" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="KD" tabindex="0">
					Expiration Date 
			</div>
<div class="col-md-8 datacolumn">
                March 14, 2026 
		</div>
</div>
<div class="row" data-index="28">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165193" data-element-required="true" data-element-type="TEXT" data-section-code="KD" tabindex="0">
					Due Dates for E.O. 12372  
			</div>
<div class="col-md-8 datacolumn">
<p class="Normal">Not Applicable</p>
</div>
</div>
<!--This variable defines that we need to start a new row. -->
<div class="heading4" data-element-has-value="true" data-element-id="165194" data-element-required="true" data-element-type="TEXT" data-section-code="KD" tabindex="0">
						Required Application Instructions 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165194" data-element-required="true" data-element-type="TEXT" data-section-code="KD">
<p class="Normal">It is critical that applicants follow the SBIR/STTR (B) Instructions in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>, except where instructed to do otherwise (in this NOFO or in a Notice from the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11164"><em>NIH Guide for Grants and Contracts</em></a>).</p>
<p class="Normal">Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in <a href="#_Section_IV._Application">Section IV</a>. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.</p>
<p class="Normal"><strong>Applications that do not comply with these instructions may be delayed or not accepted for review.</strong></p>
</div>
<div id="tocDiv">
<style>
.assist_button {
    background-color: #4CAF50; /* Green */
    border: none;
    color: white;
    padding: 8px 16px;
    text-align: center;
    text-decoration: none;
    display: inline-block;
    font-size: 14px;
}
.important {
	color: #F00;
	font-weight: bold;
	font-size 14px;
	}
</style>
<p>There are several options available to submit your application through Grants.gov to NIH and 
            Department of Health and Human Services partners. You <b>must</b> use one of these submission 
            options to access the application forms for this opportunity.</p>
<ol>
<li>Use the NIH ASSIST system to prepare, submit and track your application online.
            <form action="https://public.era.nih.gov/assist" method="post" target="new">
<input class="assist_button" name="button" type="submit" value="Apply Online Using ASSIST"/>
</form>
</li>
<li>Use an institutional system-to-system (S2S) solution to prepare and submit your application 
            to Grants.gov and <a href="https://public.era.nih.gov/commons/">eRA Commons</a> to track your 
            application. Check with your institutional officials regarding availability. <br/><br/></li>
<li>Use <a href="https://grants.gov/search-grants?oppStatuses=closed|archived|posted|forecasted&amp;fon=RFA-DA-25-048" target="_new">Grants.gov</a> 
                Workspace to prepare and submit your application and 
                <a href="http://public.era.nih.gov/commons/">eRA Commons</a> to track your application.</li>
<br/><br/>
<div class="heading1" tabindex="0">Table of Contents</div>
<div class="toc-link"><a href="#_Part_1._Overview">Part 1. Overview Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Key_Dates">Key Dates
</a></div><div class="toc-link"><a href="#_Part_2._Full">Part 2. Full Text of Announcement
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section I. Notice of Funding Opportunity Description">Section I. Notice of Funding Opportunity Description</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_II._Award_1">Section II. Award Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_III._Eligibility">Section III. Eligibility Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_IV._Application_1">Section IV. Application and Submission Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_V._Application">Section V. Application Review Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_VI._Award">Section VI. Award Administration Information
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_VII._Agency">Section VII. Agency Contacts
</a></div><div class="toc-link P_SingleIndent"><a href="#_Section_VIII._Other">Section VIII. Other Information
</a></div>
</ol></div><br/>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165196" data-element-required="true" data-element-type="TEXT" data-section-code="FOD">
<a name="_Part_2._Full"></a><h1 class="heading1">Part 2. Full Text of Announcement</h1>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165197" data-element-required="true" data-element-type="TEXT" data-section-code="FOD">
<a name="_Section I. Notice of Funding Opportunity Description"></a><h2 class="heading2">Section I. Notice of Funding Opportunity Description</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165198" data-element-required="true" data-element-type="TEXT" data-section-code="FOD">
<p><strong>Purpose</strong></p><p>The purpose of this notice of funding opportunity (NOFO) is to support applications from small business concerns (SBC) to develop technologies for commercialization to address health-related social needs that impact substance use disorders (SUD), excluding alcohol use disorder.</p><p><strong>Background</strong></p><p>In 2021, the Substance Abuse and Mental Health Services Administration (SAMHSA) noted that 61 million people ages 12 and older used illicit drugs in the past year. Nationwide, the Association of American Medical Colleges has reported 21 million people with a SUD, and just 11% of them received treatment. With so many individuals struggling with SUD, and very few receiving treatment, the SUD crisis will worsen. It will take a more comprehensive approach to address the crisis; including addressing the individual's health-related social needs (HRSN) that are influenced by their living conditions.</p><p>The health of people struggling with SUD is inextricably bound to their social environment. Social determinants of health (SDH) can directly shape health risk behaviors. Moreover, public health experts have long recognized the impact of SDH on health outcomes. While SDH are seen as the surrounding conditions of people’s existence, HRSN are the individual’s unique social conditions from five core categories established by the Centers for Medicare and Medicaid Services (CMS) Accountable Health Communities Model (housing instability, food insecurity, nonmedical transportation, utility needs, and personal safety) resulting from fundamental SDH. SDH manifest in the living conditions and resources that indirectly exacerbate the consequences of drug use. For example, inadequate housing can increase the likelihood of infectious disease transmission, stable social relationships can offer protective financial and emotional resources, and more cohesive neighborhoods are more likely to provide appropriate support and care. HRSN are displayed as people struggling with SUD being able to pay their utility bills while living in inadequate housing, being able to purchase food without sacrificing money for rent, and being able to navigate their community without concern for their personal safety. While SDH, such as poverty, homelessness, and incarceration, among others, impact behaviors that lead to SUD, being able to identify and address the unique HRSN of people struggling with SUD, by using technology, can serve as a catalyst to filling the service gaps that government and the medical community cannot do alone. The public and private sectors, utilizing the infinite capabilities of technology, can collaborate to create new paths and form new business models to address the many direct health-related social needs of people already struggling with SUD.  </p><p><strong>Research Objectives</strong></p><p>A variety of products addressing the individual-level factors of HRSN should be considered to confront SUD. Additionally, technology, such as telemedicine and mobile health applications, provide an opportunity to address HRSN with the ability to provide tested, accessible, and ongoing solutions for individuals who are the most at-risk for these risk factors that impact SUD. According to SAMHSA, technology has several advantages in addressing Substance SUD including decreased waiting periods, decreased stigma impact, and increased privacy. The advantages of technology are also exhibited in its capability to make treatment services more accessible and convenient which can aid to improve SUD outcomes and reduce disparities.  </p><p>Regarding this NOFO, a product is any source of value for the end-users and customers. A product can be a physical/tangible device as well as digital services, software as a service, or non-physical/non-tangible products (including but not limited to digital applications, digital platforms, or service models). These and other comparable examples could be considered eligible products. Products can be the result of original scientific research, recycled existing technology for SUD, extension of an observation into SUD area, development of a new business model or distribution/delivery channel that reveals currently unseen value, or the delivery of a product or service to disregarded consumers.  </p><p>The National Institute on Drug Abuse (NIDA) supports the development of evidence-based SUD care and treatment technology from multiple funding opportunities published elsewhere. The eligible small businesses can submit applications focusing on products that reduce costs, time, and/or increase access in addressing HRSN including, but not limited to, housing instability, non-medical transportation, food insecurity, utility needs, and personal safety. The products should provide the best feasible and accessible opportunities for the intended end-users to measurably improve their HRSN and SUD. Products of interest that address, but are not limited to, the following HRSN include:</p><ul><li>Access to housing services.  </li><li>Soft skills development and/or job training (e.g., in entrepreneurship, literacy and financial literacy, IT skills) for employment.  </li><li>Stigma and nurture compassion.  </li><li>Family healthy behaviors, social skills, community opportunities, and productive social involvement.</li><li>Social stability (community, tradition, faith, family), self-regulation and resilience.</li><li>Well-being (mental, physical, spiritual), communal belonging, and positive productivity.</li><li>Social support networks for recovery, engagement with care, and/or access to needed services.</li><li>Successful community reintegration for formerly incarcerated people.  </li><li>Social needs service engagement and coordination among justice-involved organizations.  </li><li>Employer education to hire, retain, and facilitate treatment for employees seeking help for SUD.</li></ul><p><strong>Applications Not Responsive to this NOFO</strong></p><p>The following will be deemed not responsive and will be returned without review</p><ul><li>Applications solely focused on the research and development of solutions to provide medical care and/or treatment.   </li><li>Applications focusing solely on health-related social needs in the context of Alcohol Use Disorders. </li></ul><p><strong>The SBIR/STTR program is a phased program.</strong></p><p>The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts, whereas in SBIR/STTR Phase II it is to continue the R&amp;D efforts to advance the technology toward ultimate commercialization.</p><p>An overall objective of the SBIR and STTR programs is to increase private sector commercialization of innovations derived from federally supported research and development. At the conclusion of an SBIR/STTR Phase II, the small business is expected to fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal).</p><p>Three types of applications are accepted in response to this NOFO:</p><p><strong>Phase I. </strong>The objective of Phase I is to establish the technical merit, feasibility, and commercial potential of the proposed R/R&amp;D efforts and to determine the quality of performance of the small business awardee organization prior to proceeding to Phase II.</p><p><strong>Fast-Track (Phase I/ Phase II) </strong>applications should include a clear rationale of feasibility of the proposed approach and/ or technology application in SUD area; demonstrate a high probability of commercialization; propose clear, appropriate, meaningful, and measurable goals (milestones) to be achieved prior to initiating Phase II; and indicate potential Phase III support/interest (non-SBIR/STTR) from future commercialization partners.</p><p>An NIH SBIR Fast-Track incorporates a submission and review process in which both Phase I and Phase II applications are submitted and reviewed together as one application to reduce or eliminate the funding gap between phases.</p><p><strong>Phase II.</strong> The objective of Phase II (as a part of Fast Track applications) is to continue the R&amp;D efforts initiated in Phase I to advance technologies to potential commercialization. Projects proposed for Phase II are based on the results achieved in Phase I (or equivalent) and aim to demonstrate scientific and technical merit and commercial potential. NIDA seeks to determine that both technical feasibility and commercial feasibility are established in Phase I before making the decision about proceeding to Phase II.</p><p><strong>Special Considerations</strong></p><p>NIDA applicants are strongly encouraged to review the guidelines and adhere to the requirements applicable to their research listed in the <a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.drugabuse.gov%2Ffunding%2Fspecial-considerations-for-nida-funding&amp;data=05%7C01%7Cyvonne.walker%40nih.gov%7C2b30605ae50740cd31fb08dad6eab2e5%7C14b77578977342d58507251ca2dc2b06%7C0%7C0%7C638058600752895551%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=RZWNDnsvUK%2BgiMQdFmQN7h9cG6ADsnh51v0XvRnqG6k%3D&amp;reserved=0">Special Considerations for NIDA Funding Opportunities and Awards</a>. Upon award, these considerations will be included in the Notice of Grant Award.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165199" data-element-required="true" data-element-type="TEXT" data-section-code="FOD">
<p class="Normal">See <a href="#_Section_VIII._Other">Section VIII. Other Information</a> for award authorities and regulations.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165200" data-element-required="false" data-element-type="TEXT" data-section-code="FOD">
<p class="Normal">Investigators proposing NIH-defined clinical trials may refer to the <a href="https://researchmethodsresources.nih.gov/">Research Methods Resources</a> website for information about developing statistical methods and study designs.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165201" data-element-required="true" data-element-type="TEXT" data-section-code="AI">
<a name="_Section_II._Award_1"></a><h2 class="heading2">Section II. Award Information</h2>
</div>
<div class="row" data-index="37">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165202" data-element-required="true" data-element-type="TEXT" data-section-code="AI" tabindex="0">
					Funding Instrument 
			</div>
<div class="col-md-8 datacolumn">
<p class="Normal">Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.</p>
</div>
</div>
<div class="row" data-index="38">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165203" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="AI" tabindex="0">
					 Application Types Allowed 
			</div>
<div class="col-md-8 datacolumn">
                New (Phase I, Fast-Track)
	<br/>
	Renewal (Phase II)
	<br/>
	Resubmission (All Phases)
	<br/>
</div>
</div>
<div class="row" data-index="40">
<div class="col-md-push-4 col-md-8 datacolumn">
<p class="Normal">The <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11116">OER Glossary</a> and the SF424 (R&amp;R) Application Guide provide details on these application types. Only those application types listed here are allowed for the NOFO.  </p>
</div>
</div>
<div class="row" data-index="41">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165206" data-element-required="true" data-element-type="SINGLE_SELECT" data-section-code="AI" tabindex="0">
					Clinical Trial? 
			</div>
<div class="col-md-8 datacolumn">
                Optional: Accepting applications that either propose or do not propose clinical trial(s) 
		</div>
</div>
<div class="row" data-index="42">
<div class="col-md-push-4 col-md-8 datacolumn">
<a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82370">Need help determining whether you are doing a clinical trial?</a>
</div>
</div>
<div class="row" data-index="43">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165208" data-element-required="true" data-element-type="TEXT" data-section-code="AI" tabindex="0">
					Funds Available and Anticipated Number of Awards  
			</div>
<div class="col-md-8 datacolumn">
<p>NIDA intends to commit $2M in FY 2025 to fund six awards.</p>
</div>
</div>
<div class="row" data-index="44">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165209" data-element-required="true" data-element-type="TEXT" data-section-code="AI" tabindex="0">
					Award Budget 
			</div>
<div class="col-md-8 datacolumn">
<p> Budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II may be requested. Please refer to current Omnibus hard cap levels for FY25 and FY26 applications. These limits are subject to change each year. </p>
</div>
</div>
<div class="row" data-index="45">
<div class="col-md-push-4 col-md-8 datacolumn">
</div>
</div>
<div class="row" data-index="46">
<div class="col-md-4 datalabel" data-element-has-value="true" data-element-id="165211" data-element-required="true" data-element-type="TEXT" data-section-code="AI" tabindex="0">
					Award Project Period 
			</div>
<div class="col-md-8 datacolumn">
<p>According to statutory guidelines, award periods normally may not exceed six months  for Phase I and 2 years for Phase II. Applicants are encouraged to propose a project duration period that is reasonable and appropriate for completion of the research project. </p>
</div>
</div>
<!--This variable defines that we need to start a new row. -->
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165212" data-element-required="true" data-element-type="TEXT" data-section-code="AI">
<p class="Normal">NIH grants policies as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a> will apply to the applications submitted and awards made from this NOFO.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165213" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<a name="_Section_III._Eligibility"></a><h2 class="heading2">Section III. Eligibility Information</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165214" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="heading4">1. Eligible Applicants</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165215" data-element-required="true" data-element-type="TEXT" data-section-code="EI" tabindex="0">
						Eligible Organizations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165215" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p style="margin-left:0in;">Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets <i>all</i> of the following criteria:</p><ol><li>Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;</li><li>Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;</li><li><strong>SBIR and STTR.</strong>  Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), an Indian tribe, ANC or NHO (or a wholly owned business entity of such tribe, ANC or NHO), or any combination of these; OR</li><li><strong>SBIR-only.</strong>  Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.  No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern, unless that single venture capital operating company, <a href="https://www.law.cornell.edu/cfr/text/13/121.702" title="Link to Non-U.S. Government Site">hedge fund</a>, or <a href="https://www.law.cornell.edu/cfr/text/13/121.702" title="Link to Non-U.S. Government Site">private equity firm</a> qualifies as a small business concern that is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States; OR</li><li><strong>SBIR and STTR.  </strong>Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with   121.705(b) concerning registration and proposal requirements.</li></ol><p>4. Has, including its affiliates, not more than 500 employees.</p><p>If the concern is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these falls under 3 (ii) or 3 (iii) above, see <a href="file:///C:/Users/mckenziene/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/13V4QPZR/Small%20Business%20Draft%20-%20Portnoy.doc#_Section_IV._Application">Section IV. Application and Submission Information</a> for additional instructions regarding required application certification.</p><p>If an Employee Stock Ownership Plan owns all or part of the concern, each stock trustee and plan member is considered an owner.</p><p>If a trust owns all or part of the concern, each trustee and trust beneficiary is considered an owner.</p><p>Definitions:</p><ul><li>Hedge fund has the meaning given that term in section 13(h)(2) of the Bank Holding Company Act of 1956 (12 U.S.C. 1851(h)(2)). The hedge fund must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State.</li><li>Portfolio company means any company that is owned in whole or part by a venture capital operating company, hedge fund, or private equity firm.</li><li>Private equity firm has the meaning given the term  private equity fund  in section 13(h)(2) of the Bank Holding Company Act of 1956 (12 U.S.C. 1851(h)(2)). The private equity firm must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State.</li><li>Venture capital operating company means an entity described in   121.103(b)(5)(i), (v), or (vi). The venture capital operating company must have a place of business located in the United States and be created or organized in the United States, or under the law of the United States or of any State.</li><li>ANC means Alaska Native Corporation.</li><li>NHO means Native Hawaiian Organization.</li></ul><p style="margin-left:0in;"><br/>SBCs must also meet the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns, other than investment companies licensed, or state development companies qualifying under the Small Business Investment Act of 1958, 15 U.S.C. 661, et seq., are affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Business concerns include, but are not limited to, any individual (sole proprietorship) partnership, corporation, joint venture, association, or cooperative. The SF424 (R&amp;R) SBIR/STTR Application Guide should be referenced for detailed eligibility information.<br/> </p><p style="margin-left:0in;"><strong>Small business concerns that are more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these are NOT eligible to apply to the NIH STTR program.</strong></p><p style="margin-left:0in;"><strong> </strong></p><p style="margin-left:0in;">Performance Benchmark Requirements<br/> </p><p style="margin-left:0in;"><strong>Phase I to Phase II Transition Rate Benchmark: </strong>In accordance with guidance from the SBA, the HHS SBIR/STTR Program is implementing the Phase I to Phase II Transition Rate benchmark required by the SBIR/STTR Reauthorization Act of 2011 and the SBIR and STTR Extension Act of 2022.The benchmark establishes a minimum number of Phase II awards the company must have received relative to a given number of Phase I awards received during the 5-fiscal year time period. The Transition Rate is calculated as the total number of SBIR and STTR Phase II awards a company received during the past 5 fiscal years divided by the total number of SBIR and STTR Phase I awards it received during the past 5 fiscal years excluding the most recently completed year. The Transition Rate requirement, agreed upon and established by all 11 SBIR agencies, was published for public comment in a Federal Register Notice on October 16, 2012 (77 FR 63410) and amended on May 23, 2013 (78 FR 30951).</p><p><br/>For SBIR and STTR Phase I applicants that have received more than 20 Phase I awards over the past 5 fiscal years (excluding the most recently-completed fiscal year): Companies that do not meet or exceed the benchmark minimum Transition Rate of 0.25 will not be eligible to apply for a Phase I, Fast-Track, or Direct Phase II (if available) award for a period of one year from the date of the application submission. This requirement does not apply to companies that have received 20 or fewer Phase I awards over the prior 5-fiscal year period.</p><p>For application deadlines that fall on or after April 5, 2023: For SBIR and STTR Phase I applicants that have received more than 50 Phase I awards over the past 5 fiscal years (excluding the most recently-completed fiscal year): Companies that do not meet or exceed the benchmark minimum Transition Rate of 0.5 will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 50 or fewer Phase I awards over the 5-fiscal year period.</p><p>On June 1 of each year, SBA will identify the companies that fail to meet minimum performance requirements. SBA calculates individual company Phase I to Phase II Transition Rates using SBIR and STTR award information across all federal agencies will notify companies and the relevant officials at the participating agencies. More information on the Phase I to Phase II Transition Rate requirement is available at SBIR.gov.</p><p><strong>Phase II to Commercialization Benchmark:</strong> In accordance with guidance from the SBA, the HHS SBIR/STTR Programs are implementing the Phase II to Commercialization Rate benchmark for Phase I applicants, as required by the SBIR/STTR Reauthorization Act of 2011 and the SBIR and STTR Extension Act of 2022. The Commercialization Rate Benchmark was published in a Federal Register notice on August 8, 2013 (<a href="http://www.gpo.gov/fdsys/pkg/FR-2013-08-08/pdf/2013-19247.pdf">78 FR 48537</a>), with a reopening of the comment period published on September 26, 2013 (78 FR 59410).</p><p>For companies that have received more than 15 Phase II awards from all agencies over the past 10 fiscal years (excluding the two most recently completed fiscal year): Companies that meet this criterion must show an average of at least $100,000 in revenues and/or investments per Phase II award or at least 0.15 (15%) patents per Phase II award resulting from these awards during the past 10- fiscal year period. Applicants that fail this benchmark will not be eligible to apply for New Phase I, Fast-track or Direct Phase II (if applicable) awards for a period of one year. This requirement does not apply to companies that have received 15 or fewer Phase II awards over the 10-fiscal year period, excluding the two most recently completed fiscal years.</p><p>For application deadlines that fall on or after April 5, 2023: For companies that have received more than 50 Phase II awards from all agencies over the past 10-fiscal years (excluding the two most recently completed Fiscal Year): Companies that meet this criterion must show an average of at least $250,000 of aggregated sales and investment per Phase II award over the past 10-fiscal year period. Applicants that fail this benchmark will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 50 or fewer Phase II awards over the 10-fiscal year period, excluding the two most recently completed fiscal years.</p><p style="margin-left:0in;">For application deadlines that fall on or after April 5, 2023: For companies that have received more than 100 Phase II awards from all agencies over the past 10-fiscal years (excluding the two most recently completed Fiscal Year): Companies that meet this criterion must show an average of at least $450,000 of aggregated sales and investment per Phase II award over the past 10-fiscal year period. Applicants that fail this benchmark will not be eligible to receive more than 20 total Phase I and Phase II awards for a period of one year from the date on which such determination is made. This requirement does not apply to companies that have received 100 or fewer Phase II awards over the 10-fiscal year period, excluding the two most recently completed fiscal years.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165216" data-element-required="true" data-element-type="TEXT" data-section-code="EI" tabindex="0">
						Foreign Institutions 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165216" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="Normal">Non-domestic (non-U.S.) Entities (Foreign Institutions) <strong>are not</strong> eligible to apply.</p>
<p class="Normal">Non-domestic (non-U.S.) components of U.S. Organizations <strong>are not</strong> eligible to apply.</p>
<p class="Normal">Foreign components, as <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11118">defined in the <em>NIH Grants Policy Statement</em></a>,<strong> may be</strong> allowed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165217" data-element-required="true" data-element-type="TEXT" data-section-code="EI" tabindex="0">
						Required Registrations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165217" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="Normal"><strong>Applicant Organizations</strong></p>
<p class="Normal">Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&amp;R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications</a> states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.</p>
<ul>
<li class="Normal"><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82390">System for Award Management (SAM) </a> Applicants must complete and maintain an active registration, <strong>which requires renewal at least annually</strong>. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.

	<ul>
<li class="Normal">Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.</li>
</ul>
</li>
<li class="Normal"><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82410">SBA Company Registry</a>  See <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a> for instructions on how to register and how to attach proof of registration to your application package. Applicants must have a UEI to complete this registration. SBA Company registration is <strong>NOT</strong> required before SAM, Grants.gov or eRA Commons registration.</li>
<li class="Normal"><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=11123">eRA Commons</a> - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.</li>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82300">Grants.gov</a>   Applicants must have an active SAM registration in order to complete the Grants.gov registration.</li>
</ul>
<p class="Normal"><br/>
<strong>Program Directors/Principal Investigators (PD(s)/PI(s)) </strong></p>
<p class="Normal">All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165218" data-element-required="true" data-element-type="TEXT" data-section-code="EI" tabindex="0">
						Eligible Individuals (Program Director/Principal Investigator) 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165218" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="Normal" paraeid="{8fb84fd1-93e3-4828-abaa-b5fd161c91fb}{67}" paraid="525357993">Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-019.html" rel="noreferrer noopener" target="_blank">NOT-OD-22-019</a>. </p>
<p class="Normal" paraeid="{8fb84fd1-93e3-4828-abaa-b5fd161c91fb}{85}" paraid="1450619877">For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&amp;R) Application Guide.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165219" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p style="margin-left:0in;">Under the SBIR program, for both Phase I and Phase II, the primary employment of the PD/PI must be with the small business concern at the time of award and during the conduct of the proposed project. For projects with multiple PDs/PIs, at least one must meet the primary employment requirement. Occasionally, deviations from this requirement may occur.<br/> </p><p style="margin-left:0in;"> </p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165220" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="Normal">The <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a> should be referenced for specific details on eligibility requirements. For institutions/organizations proposing multiple PDs/PIs, see Multiple Principal Investigators section of the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165221" data-element-required="false" data-element-type="TEXT" data-section-code="EI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165222" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="heading4">2. Cost Sharing</p>
<p class="Normal">This NOFO does not require cost sharing as defined in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11126">NIH Grants Policy Statement</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165223" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="heading4">3. Additional Information on Eligibility</p>
<p class="heading4">Number of Applications</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165224" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p class="Normal">Applicant organizations may submit more than one application, provided that each application is scientifically distinct.</p>
<p class="Normal">NIH will not accept similar grant applications with essentially the same research focus from the same applicant organization. This includes derivative or multiple applications that propose to develop a single product, process, or service that, with non-substantive modifications, can be applied to a variety of purposes. Applicants may <strong>not</strong> simultaneously submit identical/essentially identical applications under both this funding opportunity and any other HHS funding opportunity, including the SBIR and STTR Parent announcements.</p>
<p class="Normal">NIH will not accept duplicate or highly overlapping applications under review at the same time, per<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82415"> NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application</a>. This means that the NIH will not accept:</p>
<ul>
<li class="Normal">A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.</li>
<li class="Normal">A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.</li>
<li class="Normal">An application that has substantial overlap with another application pending appeal of initial peer review (<a>see</a> <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications</a>).</li>
</ul>
<p class="Normal">A Phase I awardee may submit a Phase II application either before or after expiration of the Phase I budget period, unless the awardee elects to submit a Phase I and Phase II application concurrently under the Fast-Track procedure. To maintain eligibility to seek Phase II or IIB support, a Phase I awardee should submit a Phase II application, and a Phase II awardee should submit a Phase IIB application, within the first six due dates following the expiration of the Phase I or II budget period, respectively.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165225" data-element-required="false" data-element-type="TEXT" data-section-code="EI">
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165226" data-element-required="true" data-element-type="TEXT" data-section-code="EI" tabindex="0">
						Contractual/Consortium Arrangements 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165226" data-element-required="true" data-element-type="TEXT" data-section-code="EI">
<p>In Phase I, normally, two-thirds or 67% of the research or analytical effort is carried out by the small business concern. The total amount of all consultant and contractual arrangements to third parties for portions of the scientific and technical effort is generally not more than 33% of the total amount requested (direct, F&amp;A/indirect, and fee).<br/><br/>In Phase II, normally, one-half or 50% of the research or analytical effort is carried out by the small business concern. The total amount of consultant and contractual arrangements to third parties for portions of the scientific and technical effort is generally not more than 50% of the total Phase II amount requested (direct, F&amp;A/indirect, and fee).</p><p>A small business concern may subcontract a portion of its SBIR or STTR award to a Federal laboratory within the limits above. A Federal laboratory, as defined in 15 U.S.C.   3703, means any laboratory, any federally funded research and development center, or any center established under 15 U.S.C.    3705 &amp; 3707 that is owned, leased, or otherwise used by a Federal agency and funded by the Federal Government, whether operated by the Government or by a contractor.</p><p style="margin-left:0in;">The basis for determining the percentage of work to be performed by each of the cooperative parties in Phase I or Phase II will be the total of the requested costs attributable to each party, unless otherwise described and justified in  Consortium/Contractual Arrangements  of the PHS 398 Research Plan component of SF424 (R&amp;R) application forms.</p><p>Additional details are contained in the SF424 (R&amp;R) SBIR/STTR Application Guide.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165227" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<a name="_Section_IV._Application_1"></a><h2 class="heading2">Section IV. Application and Submission Information</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165228" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">1. Requesting an Application Package</p>
<p class="Normal">The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in <a href="#_Required_Application_Instructions">Part 1</a> of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165229" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">2. Content and Form of Application Submission</p>
<p class="Normal">It is critical that applicants follow the SBIR/STTR (B) Instructions in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>, except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165230" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
<h4> Letter of Intent</h4><p>Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.</p><p>By the date listed in <a href="#_Part_1._Overview">Part 1. Overview Information</a>, prospective applicants are asked to submit a letter of intent that includes the following information:</p><ul><li>Descriptive title of proposed activity</li><li>Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)</li><li>Names of other key personnel</li><li>Participating institution(s)</li><li>Number and title of this funding opportunity</li></ul><p>The letter of intent should be sent to: <a href="mailto:NIDALetterofIntent@mail.nih.gov">NIDALetterofIntent@mail.nih.gov</a></p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165231" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						Page Limitations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165231" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal">All page limitations described in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a> and the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=61134">Table of Page Limits</a> must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165232" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						Instructions for Application Submission 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165232" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal">The following section supplements the instructions found in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a> and should be used for preparing an application to this NOFO.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165233" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						 SF424(R&amp;R) Cover 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165233" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal">All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165235" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						SF424(R&amp;R) Project/Performance Site Locations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165235" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165237" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						SF424(R&amp;R) Other Project Information 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165237" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed with the following additional instructions:</p>
</div>
<div>
<p><b>Facilities &amp; Other Resources</b></p>
<p>In addition to describing the scientific environment and the company support, the applicant must describe the business environment and resources, or how the company will obtain access to the appropriate business resources, for completing and commercializing the proposed product or service. This includes any relevant intellectual property associated with the project necessary to facilitate commercialization.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165239" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal"><strong>Other Attachments:</strong></p>
<p class="Normal">1. SBIR Application Certification for small business concerns majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms</p>
<p class="Normal">Applicant small business concerns that are majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms (e.g. majority VCOC-owned) are required to submit a Certification at time of their application submission per the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31421">SBIR Policy Directive</a>.  Follow the instructions below. </p>
<p class="Normal">Applicants small business concerns who are more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these (i.e. NOT majority VCOC-owned) should NOT fill out this certification and should NOT attach it to their application package.</p>
<ol style="list-style-type:lower-alpha;">
<li class="Normal">Download the  VCOC Certification.pdf  at the <a href="//grants.nih.gov/grants/forms.htm#sbir">NIH SBIR Forms</a> webpage. </li>
</ol>
<ol style="list-style-type:lower-alpha;">
<li class="Normal" value="2">Answer the 3 questions and check the certification boxes.</li>
</ol>
<ol style="list-style-type:lower-alpha;">
<li class="Normal" value="3">The authorized business official must sign the certification.</li>
</ol>
<ol style="list-style-type:lower-alpha;">
<li class="Normal" value="4">Save the certification using the original file name.  The file must be named  SBIR Application VCOC Certification.pdf .  DO NOT CHANGE OR ALTER THE FILE NAME.  Changing the file name may cause delays in the processing of your application.</li>
</ol>
<ol style="list-style-type:lower-alpha;">
<li class="Normal" value="5">When you are completing the application package, attach this certification as a separate file by clicking "Add Attachments" located to the right of Other Attachments field on the  Research and Related Other Project Information  form.</li>
</ol>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165241" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						 SF424(R&amp;R) Senior/Key Person Profile Expanded 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165241" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165243" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						 R&amp;R Budget 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165243" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165245" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						R&amp;R Subaward Budget 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165245" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165247" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						PHS 398 Cover Page Supplement 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165247" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165249" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						PHS 398 Research Plan 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165249" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>SBIR/STTR Information Form</p><p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed, with the following additional instructions: </p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165250" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
<p><strong>For the Fast Track applications:</strong></p><p>1) If the proposed research project is the result of re-purposing an existing technology for a new use or extending a research observation into SUD area, a solid foundation (i.e., literature review, totality of evidence, relevant proof-of-concept) to support continued development of the technology for the proposed SUD indication/use should be included in Research Strategy section of the grant application.</p><p>2) Milestones (required for fast-track applications) are clear, appropriate, meaningful and measurable goals that should be achieved prior to initiating Phase II and associated timelines. A milestone is a marker in a project that signifies the point at which a major uncertainty in the project is resolved. Milestones show key events and map forward movement in the project plan. Milestones for Phase I must be written with the goal of addressing all significant questions of technical and commercial feasibility. Phase I milestones must be quantitative, not qualitative. Milestones must be written utilizing the appropriate controls. All milestones must be achieved prior to initiating Phase II. Phase I milestones must be written to allow to evaluate the claims that their completion fully justifies the initiation of Phase II.</p><p><strong>For Phase I projects</strong>, include a plan for participation, pending NIH approval, to the I-Corps program at NIH (<a href="https://sbir.cancer.gov/programseducation/icorps">https://sbir.cancer.gov/programseducation/icorps</a>). I-Corps at NIH is an entrepreneurial training program in which participants are required to interview at least 100 stakeholders to better identify market needs and product-specific commercialization opportunities. </p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165251" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal"><strong>Resource Sharing Plans</strong>:<br/>
<br/>
Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&amp;R) Application Guide.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165252" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165253" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal"><strong>Other Plan(s)</strong><br/>
<br/>
All instructions in the SF424 (R&amp;R) Application Guide must be followed, with the following additional instructions:</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165254" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
<ul><li>All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applicants are required to address a Data Management and Sharing Plan, regardless of the amount of direct costs requested for any one year. However, SBIR and STTR recipients may retain the rights to data generated during the performance of an SBIR or STTR award for up to 20 years after the award date, per the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program Policy Directive. An acceptable Data Management and Sharing plan can reference and incorporate these data rights. Further information about SBIR and STTR data rights are enumerated in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_18/18.5.5_administrative_requirements.htm#Intellec:~:text=behavior%20of%20individuals.-,18.5.5.2%20Intellectual%20Property,-Rights%20to%20data">NIH GPS</a>.</li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165255" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p><strong>Appendix:</strong></p>
<p>Note that Phase I SBIR/STTR Appendix materials are not permitted.  Only limited items are allowed in the Appendix of other small business applications.  The instructions for the Appendix of the Research Plan are described in the SF424 (R&amp;R) Application Guide; any instructions provided here are in addition to the SF424 (R&amp;R) Application Guide Instructions.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165256" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165257" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						PHS Human Subjects and Clinical Trials Information 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165257" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal">When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&amp;R) Application Guide, with the following additional instructions:</p>
<p class="Normal">If you answered  Yes  to the question  Are Human Subjects Involved?  on the R&amp;R Other Project Information form, you must include at least one human subjects study record using the <strong>Study Record: PHS Human Subjects and Clinical Trials Information </strong>form or <strong>Delayed Onset Study</strong> record.</p>
<p class="Normal"><strong>Study Record: PHS Human Subjects and Clinical Trials Information</strong></p>
<p class="Normal">All instructions in the SF424 (R&amp;R) Application Guide must be followed.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165258" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165259" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal"><strong>Delayed Onset Study</strong></p>
<p class="Normal">Note: <a href="https://grants.nih.gov/grants/glossary.htm#DelayedOnsetStudy">Delayed onset</a> does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&amp;R) Application Guide must be followed.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165260" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165261" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						PHS Assignment Request Form 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165261" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>All instructions in the SF424 (R&amp;R) SBIR/STTR Application Guide must be followed.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165263" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">3. Unique Entity Identifier and System for Award Management (SAM)</p>
<p class="Normal">See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), eRA Commons, and Grants.gov</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165264" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">4. Submission Dates and Times</p>
<p class="Normal"><a href="#_Part_1._Overview" style="font-family: Verdana; font-size: 10pt;">Part I. Overview Information</a> contains information about Key Dates and time. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82380" style="font-family: Verdana; font-size: 10pt;">Federal holiday</a>, the application deadline is automatically extended to the next business day.</p>
<p class="Normal">Organizations must submit applications to <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11128" target="_blank">Grants.gov</a> (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11123" target="_blank">eRA Commons</a>, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications</a>.</p>
<p class="Normal">Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.</p>
<p class="Normal">Information on the submission process and a definition of on-time submission are provided in the the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply   Application Guide</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165265" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">5. Intergovernmental Review (E.O. 12372)</p>
<p class="Normal">This initiative is not subject to <a href="https://grants.nih.gov/grants/policy/nihgps/html5/section_10/10.10.1_executive_orders.htm">intergovernmental review</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165266" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">6. Funding Restrictions</p>
<p class="Normal">All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120" style="font-family: Verdana; font-size: 10pt;">NIH Grants Policy Statement</a>.</p>
<p class="Normal">Pre-award costs are allowable only as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11143">NIH Grants Policy Statement</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165267" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165268" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="heading4">7. Other Submission Requirements and Information</p>
<p class="Normal">Applications must be submitted electronically following the instructions described in the SF424 (R&amp;R) SBIR/STTR Application Guide.  Paper applications will not be accepted.</p>
<p class="Normal">Applicants must complete all required registrations before the application due date. <a href="#_Section_III._Eligibility">Section III. Eligibility Information</a> contains information about registration.</p>
<p class="Normal">For assistance with your electronic application or for more information on the electronic submission process, visit <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82400" style="color:blue; text-decoration:underline">How to Apply   Application Guide</a>. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the <a href="https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/dealing-with-system-issues.htm" style="color:blue; text-decoration:underline">Dealing with System Issues</a> guidance. For assistance with application submission, contact the Application Submission Contacts in <a href="#_Section_VII._Agency">Section VII</a>.</p>
<p class="Normal" style="margin-left: 25px;"><strong>Important reminders:</strong></p>
<p class="Normal" style="margin-left: 25px;">All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.</p>
<p class="Normal" style="margin-left: 25px;">The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&amp;R) Application Guide.</p>
<p class="Normal" style="margin-left: 25px;">See <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11146">more tips</a> for avoiding common errors.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165269" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p>Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by NIDA, NIH. Applications that are incomplete, non-compliant, and/or nonresponsive will not be reviewed. </p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165270" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165271" data-element-required="true" data-element-type="TEXT" data-section-code="ASI" tabindex="0">
						Post Submission Materials 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165271" data-element-required="true" data-element-type="TEXT" data-section-code="ASI">
<p class="Normal">Applicants are required to follow the instructions for post-submission materials, as described in <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82299">the policy</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165272" data-element-required="false" data-element-type="TEXT" data-section-code="ASI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165273" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<a name="_Section_V._Application"></a><h2 class="heading2">Section V. Application Review Information</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165274" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4">1. Criteria</p>
<p class="Normal">Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11149">NIH mission</a> are evaluated for scientific and technical merit through the NIH peer review system.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165276" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165277" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal">A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165278" data-element-required="true" data-element-type="TEXT" data-section-code="ARI" tabindex="0">
						Overall Impact 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165278" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p>Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165279" data-element-required="true" data-element-type="TEXT" data-section-code="ARI" tabindex="0">
						Scored Review Criteria 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165279" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p>Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165280" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Significance</p>
<p class="Normal" style="margin-left: 25px;">Does the project and proposed product or service address an important problem, a critical barrier to progress, or unmet need in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims and commercialization of the resulting product or service change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Does the proposed project have commercial potential to lead to a marketable product, process or service? In the case of Phase II, Fast-Track, and Phase II Competing Renewals, does the Commercialization Plan demonstrate a high probability of commercialization? How strong is the described market opportunity in the Commercialization Plan including: (i) the product or service being developed; (ii) target customers; and (iii) how the product will solve a demonstrated customer need?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165281" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><i><strong>Specific to this NOFO: </strong></i></p><ul><li style="margin-left:25px;">If the product/technology proposed for development is a platform technology that was initially developed for a non-SUD indication/use, then to what extent have the SBC activities provided a solid foundation (i.e., literature review, totality of evidence, relevant proof-of- concept) to support continued development of the technology for the proposed SUD indication/use? </li><li style="margin-left:25px;">How compelling is the justification for the development of the proposed product or service in terms of potential advances in clinical practice, public health, and/or patient quality of life?  </li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165282" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><strong>In addition, for applications involving clinical trials</strong></p><p style="margin-left:25px;">Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165283" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<h4 style="margin-left:25px;">Investigator(s)</h4><p style="margin-left:25px;">Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project and will they devote sufficient effort to successfully complete the proposed aims? Do the PD(s)/PI(s) have appropriate experience and training to lead this project? If so, have they demonstrated an ongoing record of accomplishments in their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? For projects in later stages, does the team have expertise to commercialize the technology/service/product?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165284" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165285" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><strong>In addition, for applications involving clinical trials</strong></p><p style="margin-left:25px;">With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165286" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Innovation</p>
<p class="Normal" style="margin-left: 25px;">Does the proposed product or service represent an innovative approach to addressing an important problem, barrier to progress, or unmet need in research or clinical practice? Does the end product or service proposed in application challenge and seek to shift current research or clinical practice paradigms? Will the end product or service proposed have significant advantages over existing approaches or methodologies, instrumentation, or interventions or those in development?</p>
<p class="Normal" style="margin-left: 25px;">In the case of Phase II, Fast-Track, and Phase II Competing Renewals, does the small business present a reasonable plan to create a temporal barrier against other companies aiming to provide a similar solution, including protecting the intellectual property relevant to the product and technology(ies) being studied or used during the project?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165287" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165288" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><strong>In addition, for applications involving clinical trials</strong></p><p style="margin-left:25px;">Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165289" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Approach</p>
<p class="Normal" style="margin-left: 25px;">Are the research aims appropriate for the current stage of development? Do the aims represent the necessary steps to further advance the development of the product or service? Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed? For a Phase I application, are there clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?</p>
<p class="Normal" style="margin-left: 25px;">For a Phase I, will the strategy establish feasibility, and will particularly risky aspects be managed? Are there clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II?</p>
<p class="Normal" style="margin-left: 25px;">For a Fast-Track, are there clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II? Will successful completion of the research aims significantly advance development of the proposed product or service toward eventual commercialization?</p>
<p class="Normal" style="margin-left: 25px;">For a Phase II, will successful completion of the research aims significantly advance development of the proposed product or service toward eventual commercialization? How well did the applicant demonstrate progress toward meeting the Phase I objectives, demonstrating feasibility, and providing a solid foundation for the proposed Phase II activity?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165290" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><i><strong>Specific to this NOFO: </strong></i></p><ul><li>For Phase I, to what extent will the strategy establish feasibility, and how well will particularly risky aspects be managed?</li><li>For Phase I, how clear, appropriate, and measurable are the goals (milestones), included for each aim, that should be achieved prior to initiating Phase II?</li><li>For a Fast-Track, to what extent were the Phase I milestones (go/no go, pivot), that will determine a transition to Phase II, clearly stated, defined, and associated with specific, measurable, achievable, relevant, and time-bound deliverables?</li><li>For a Fast-Track, to what extent were two separate sets of milestones and associated specific, measurable, achievable, relevant, and time-bound deliverables proposed, one set for Phase I and another set for Phase II?</li><li>For Phase II, to what extent will the successful completion of the research aims significantly advance development of the proposed product or service toward eventual commercialization?</li><li>How well did the applicant demonstrate progress toward meeting the Phase I objectives, demonstrating feasibility, and providing a solid foundation for the proposed Phase II activity?</li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165291" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal" style="margin-left: 25px;">If the project involves human subjects and/or NIH-defined clinical research, are the plans to address:</p>
<p class="Normal" style="margin-left: 25px;">1) the protection of human subjects from research risks, and</p>
<p class="Normal" style="margin-left: 25px;">2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165292" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165293" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><strong>In addition, for applications involving clinical trials</strong></p><p style="margin-left:25px;">Does the application adequately address the following, if applicable</p><p style="margin-left:25px;"><i>Study Design</i></p><p style="margin-left:25px;">Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?</p><p style="margin-left:25px;">Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?</p><p style="margin-left:25px;">Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?</p><p style="margin-left:25px;"><i>Data Management and Statistical Analysis</i></p><p style="margin-left:25px;">Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165294" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Environment</p>
<p class="Normal" style="margin-left: 25px;">Will the scientific and business environment in which the work will be done contribute to the probability of success and eventual commercialization? Are the small business support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangement?</p>
<p class="Normal" style="margin-left: 25px;">For a Phase I, does the company have appropriate business expertise and resources, or have they identified appropriate business resources, to accomplish the aims of this project and support commercialization of the proposed product or service?</p>
<p class="Normal" style="margin-left: 25px;">For a Phase II or Fast-Track, does the applicant have access to the business experts and resources needed to accomplish the aims of this project and to commercialize the proposed product or service?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165295" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><i><strong>Specific to this NOFO:</strong></i></p><ul><li>For Phase I, to what extent does the company, have appropriate business expertise and resources, or have they identified appropriate business resources, to accomplish the aims of this project and support the commercialization of the proposed product or service?</li><li>For Phase II or Fast-Track, to what extent does the applicant have access to the business experts and resources needed to accomplish the aims of this project and to commercialize the proposed product or service?</li><li>If proposed, how appropriate are the administrative, data coordinating, enrollment, and laboratory/testing centers, appropriate for the trial proposed?</li><li>How adequately does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? </li><li>How appropriate are the plans to add or drop enrollment centers, as needed, appropriate?</li><li>If international site(s) is/are proposed, how adequately does the application address the complexity of executing the clinical trial?</li><li>If multi-sites/centers, how strong is the evidence of the ability of the individual site or center to (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure? </li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165296" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;"><strong>In addition, for applications involving clinical trials</strong></p><p style="margin-left:25px;">If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?</p><p style="margin-left:25px;">Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?</p><p style="margin-left:25px;">If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?</p><p style="margin-left:25px;">If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165297" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165298" data-element-required="true" data-element-type="TEXT" data-section-code="ARI" tabindex="0">
						Additional Review Criteria 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165298" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<h4 style="margin-left:25px;">Study Timeline</h4><p style="margin-left:25px;"><strong>Specific to applications involving clinical trials</strong></p><p style="margin-left:25px;">Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?</p><p style="margin-left:25px;">Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165299" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165300" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Phase II Applications</p>
<p class="Normal" style="margin-left: 25px;">For Phase II Applications, how well did the applicant demonstrate progress toward meeting the Phase I (or Phase I-like) objectives, demonstrating feasibility, and providing a solid foundation for the proposed Phase II activity?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165301" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165302" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Phase I/Phase II Fast-Track Applications</p>
<p class="Normal" style="margin-left: 25px;">For Phase I/Phase II Fast-Track Applications, reviewers will consider the following:</p>
<p class="Normal" style="margin-left: 25px;">1. Does the Phase I application specify clear, appropriate, measurable goals (milestones) that should be achieved prior to initiating Phase II?</p>
<p class="Normal" style="margin-left: 25px;">2. To what extent was the applicant able to obtain letters of interest, additional funding commitments, and/or resources from the private sector or non-SBIR/STTR funding sources that would enhance the likelihood for commercialization?</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165303" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165350" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Commercialization (Phase II and Fast-Track Only)</p>
<p class="Normal" style="margin-left: 25px;">For Phase II and Phase I/Phase II Fast-Track Applications, reviewers will consider the following:</p>
<p class="Normal" style="margin-left: 25px;">How well does the applicant present the market opportunity, including market segments, that its product or technology will address? Does the applicant understand the barriers to commercialization of its product or service (e.g., regulatory approval, insurance reimbursement, competitive products, customer preferences)? Does the applicant have appropriate strategies to address these barriers?</p>
<p class="Normal" style="margin-left: 25px;">Does the applicant provide appropriate post-SBIR product development and commercialization milestones and explain how it will achieve these milestones? Does the applicant present a plan for funding the development and commercialization of the product or service? If applicable, did the applicant obtain letters of interest or commitment for such funding and/or resources?</p>
<p class="Normal" style="margin-left: 25px;">Are the small business executives, management team, and business experts well suited to advance the development and commercialization of the proposed product or service? If not, is there a plan in place to add the necessary expertise as the product advances towards commercialization?</p>
<p class="Normal" style="margin-left: 25px;">Is there a sound strategy for driving product adoption and generating revenue from the product or service (e.g., product sales, licensing, partnerships)?</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165304" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Protections for Human Subjects</p>
<p class="Normal" style="margin-left: 25px;">For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.</p>
<p class="Normal" style="margin-left: 25px;">For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11175">Guidelines for the Review of Human Subjects</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165305" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Inclusion of Women, Minorities, and Individuals Across the Lifespan</p>
<p class="Normal" style="margin-left: 25px;">When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11174">Guidelines for the Review of Inclusion in Clinical Research</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165306" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Vertebrate Animals</p>
<p class="Normal" style="margin-left: 25px;">The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11150">Worksheet for Review of the Vertebrate Animals Section</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165307" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Biohazards</p>
<p class="Normal" style="margin-left: 25px;">Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165308" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Resubmissions</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165309" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;">For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous review and changes made to the project.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165310" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Phase IIB Competing Renewals</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165311" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;">Not Applicable.  </p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165312" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Revisions</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165313" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p style="margin-left:25px;">Not Applicable.  </p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165314" data-element-required="true" data-element-type="TEXT" data-section-code="ARI" tabindex="0">
						Additional Review Considerations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165314" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal">As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.</p>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165315" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165316" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4">Applications with Foreign Components</p>
<p class="Normal">Reviewers will consider whether work to be performed outside of the United States is thoroughly justified, based on a rare and unique circumstance, and necessary to the overall completion of the project.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165317" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Select Agent Research</p>
<p class="Normal" style="margin-left: 25px;">Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165318" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Resource Sharing Plans</p>
<p class="Normal" style="margin-left: 25px;">Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., <a href="https://sharing.nih.gov/other-sharing-policies/model-organism-sharing-policy#policy-overview">Sharing Model Organisms</a>) or the rationale for not sharing the resources, is reasonable.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165319" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Authentication of Key Biological and/or Chemical Resources:</p>
<p class="Normal" style="margin-left: 25px;">For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165320" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4" style="margin-left: 25px;">Budget and Period of Support</p>
<p class="Normal" style="margin-left: 25px;">Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165321" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<h4>2. Review and Selection Process </h4><p>Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIDA, in accordance with <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11154">NIH peer review policies and practices</a>, using the stated <a href="file:///C:/Users/mckenziene/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/13V4QPZR/Small%20Business%20Draft%20-%20Portnoy.doc#_1._Criteria">review criteria</a>. Assignment to a Scientific Review Group will be shown in the eRA Commons.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165322" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal">As part of the scientific peer review, all applications will receive a written critique.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165323" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal">Applications may undergo a committee process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165324" data-element-required="false" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal"><a href="https://grants.nih.gov/grants/policy/nihgps/html5/section_2/2.4.2_appeals_of_initial_scientific_review.htm">Appeals</a> of initial peer review will not be accepted for applications submitted in response to this NOFO.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165325" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p>Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Drug Abuse. The following will be considered in making funding decisions:</p><ul><li>Scientific and technical merit of the proposed project as determined by scientific peer review.</li><li>Relevance of the proposed project to program priorities.</li><li>Potential for commercialization and public health impact.</li><li>For Phase II applications: results of Phase I (or equivalent) clearly indicating that both technical feasibility and commercial feasibility were established, and the scientific/technical merit and commercial potential of the project proposed in Phase II.</li><li>For applicants who received preceding SBIR and STTR grants: quality of prior performance and evidence of Phase III activities.</li><li>Availability of funds. </li><li>Security risk as assessed by the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82425">HHS Due Diligence Program</a>.</li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165351" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="Normal"><strong>Disclosure Requirements Regarding Ties to Foreign Countries</strong></p>
<p class="Normal">Upon request applicants are required to disclose all funded and unfunded relationships with foreign countries, using the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82426">Required Disclosures of Foreign Affiliations or Relationships to Foreign Countries</a> form (referred to as the  Disclosure Form  hereafter), for all owners and covered individuals. A  covered individual  is defined as all senior key personnel identified by the SBC in the application (i.e., individuals who contribute to the scientific development or execution of a project in a substantive, measurable way).</p>
<p class="Normal">Upon request, applicants must submit the completed Disclosure Form and any additional agency-specific information electronically in eRA Commons via the Just-In-Time (JIT) process as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82418">NIH Grants Policy Statement (GPS) Section 2.5.1 Just-in-Time Procedures</a>. Applicants must continue to comply with NIH Other Support disclosure requirements as provided in NIH GPS Section 2.5.1 and may be required to provide similar information on the Disclosure Form for covered individuals identified in the application. If participating in this NOFO, SBC applicants applying to CDC and FDA will follow each agency’s policies for submitting additional documents during the pre-award process. Applicants that do not submit the completed Disclosure Form during the JIT process will be deemed noncompliant and not be considered for funding.</p>
<p class="Normal"><strong>Denial of Awards</strong></p>
<p class="Normal">Applicants are encouraged to consider whether their entity’s relationships with <a href="https://www.sbir.gov/foreign_disclosures">foreign countries of concern</a> will pose a security risk. Prior to issuing an award, NIH (and, CDC or, FDA, as applicable) will determine whether the SBC submitting the application:</p>
<ul>
<li class="Normal">has an owner or covered individual that is party to a malign foreign talent recruitment program;</li>
<li class="Normal">has a business entity, parent company, or subsidiary located in the People’s Republic of China or another <a href="https://www.sbir.gov/foreign_disclosures">foreign country of concern</a>; or</li>
<li class="Normal">has an owner or covered individual that has a foreign affiliation with a research institution located in the People’s Republic of China or another foreign country of concern.</li>
</ul>
<p class="Normal">A finding of foreign involvement with countries of concern will not necessarily disqualify an applicant. Final award determinations will be based on the above finding of foreign involvement and whether
 the applicant's involvement falls within any of the following risk criteria, per the Act:
</p>
<ul>
<li class="Normal">interfere with the capacity for activities supported by NIH, CDC, or FDA to be carried out;</li>
<li class="Normal">create duplication with activities supported by NIH, CDC, or FDA;</li>
<li class="Normal">present concerns about conflicts of interest;</li>
<li class="Normal">were not appropriately disclosed to NIH, CDC, or FDA;</li>
<li class="Normal">violate Federal law or terms and conditions of NIH, CDC, or FDA; or</li>
<li class="Normal">pose a risk to national security.</li>
</ul>
<p class="Normal">Generally, NIH, CDC, and FDA will not provide SBC applicants the opportunity to address any identified security risks prior to award.  NIH, CDC, and FDA will not issue an award under the SBIR/STTR program if the covered relationship with a foreign country of concern identified in this guidance is determined to fall under any of the criteria provided
.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165326" data-element-required="true" data-element-type="TEXT" data-section-code="ARI">
<p class="heading4">3. Anticipated Announcement and Award Dates</p>
<p class="Normal">After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11123">eRA Commons</a>. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.</p>
<p class="Normal">Information regarding the disposition of applications is available in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82416">NIH Grants Policy Statement Section 2.4.4 Disposition of Applications</a>.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165327" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<a name="_Section_VI._Award"></a><h2 class="heading2">Section VI. Award Administration Information</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165328" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p class="heading4">1. Award Notices</p>
<p class="Normal">If the application is under consideration for funding, NIH will request "just-in-time" (JIT) information from the applicant as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82418">NIH Grants Policy Statement</a>. SBIR and STTR applicants under consideration for award will be required to submit the SBA U.S. Small Business Administration (SBA) issued the Required Disclosures of Foreign Affiliations or Relationships to Foreign Countries form during the JIT process. Applicants that fail to submit a Disclosure Form will not be considered for funding.</p>
<p class="Normal">A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.</p>
<p class="Normal">Recipients must comply with any funding restrictions described in <a href="#">Section IV.6. Funding Restrictions</a>. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.</p>
<p class="Normal">Any application awarded in response to this NOFO will be subject to terms and conditions found on the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/part_ii_subpart_b.htm">Award Conditions and Information for NIH Grants</a> website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165329" data-element-required="false" data-element-type="TEXT" data-section-code="AAI">
<p class="Normal">Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.</p>
<p class="Normal">ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain  applicable clinical trials  on the ClinicalTrials.gov Protocol Registration and Results System Information Website (<a href="https://register.clinicaltrials.gov/">https://register.clinicaltrials.gov</a>). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see <a href="https://grants.nih.gov/policy/clinical-trials/reporting/index.htm">https://grants.nih.gov/policy/clinical-trials/reporting/index.htm</a></p>
<p class="Normal">Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.</p>
<p class="Normal">Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at <a href="//grants.nih.gov/grants/policy/hs/data_safety.htm">http://grants.nih.gov/grants/policy/hs/data_safety.htm</a> and in the application instructions (SF424 (R&amp;R) and PHS 398).</p>
<p class="Normal">Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165330" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p class="heading4">2. Administrative and National Policy Requirements</p>
<p class="Normal">All NIH grant and cooperative agreement awards include the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a> as part of the NoA. For these terms of award, see the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11157">NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General</a> and <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11159">Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities</a>, including of note, but not limited to:</p>
<ul>
<li class="Normal"><a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_3/3.1_federalwide_standard_terms_and_conditions_for_research_grants.htm">Federal-wide Standard Terms and Conditions for Research Grants</a></li>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82417">Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment</a></li>
<li class="Normal"><a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4.2.1_acknowledgement_of_federal_funding.htm">Acknowledgment of Federal Funding</a></li>
</ul>
<p class="Normal">If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.</p>
<p class="Normal">Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS will be required to complete an HHS Assurance of Compliance form (<a href="https://ocrportal.hhs.gov/ocr/aoc/instruction.jsf">HHS Assurance of Compliance form (HHS 690)</a>) in which the recipient agrees, as a condition of receiving the grant, to administer programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, age, sex and disability, and agreeing to comply with federal conscience laws, where applicable. This includes ensuring that entities take meaningful steps to provide meaningful access to persons with limited English proficiency; and ensuring effective communication with persons with disabilities. Where applicable, Title XI and Section 1557 prohibit discrimination on the basis of sexual orientation, and gender identity, The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.hhs.gov%2Fcivil-rights%2Ffor-providers%2Fprovider-obligations%2Findex.html&amp;data=05%7C01%7Ccarrie.mitchell%40nih.gov%7Ce8bc304bfdb644bb556e08dac343ad36%7C14b77578977342d58507251ca2dc2b06%7C0%7C0%7C638036992699510830%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=AY%2F1fYgD%2Bbumf5GYC6piwPsEJ1H0G3yetf%2FtOjaSPuc%3D&amp;reserved=0">https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html</a> and <a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.hhs.gov%2Fcivil-rights%2Ffor-individuals%2Fnondiscrimination%2Findex.html&amp;data=05%7C01%7Ccarrie.mitchell%40nih.gov%7Ce8bc304bfdb644bb556e08dac343ad36%7C14b77578977342d58507251ca2dc2b06%7C0%7C0%7C638036992699510830%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=FVdcrY38rDvkbEyNG7CJUvclJYXUTpr1UiZmJQY0GoI%3D&amp;reserved=0">https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html</a>.</p>
<p class="Normal">HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.</p>
<ul>
<li class="Normal">For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals see <a href="https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html">https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html</a> and <a href="https://www.lep.gov/">https://www.lep.gov</a>.</li>
</ul>
<ul>
<li class="Normal">For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <a href="https://www.hhs.gov/civil-rights/for-individuals/disability/index.html">https://www.hhs.gov/civil-rights/for-individuals/disability/index.html</a>.</li>
</ul>
<ul>
<li class="Normal">HHS funded health and education programs must be administered in an environment free of sexual harassment, see <a href="https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html">https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html</a>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <a href="https://grants.nih.gov/grants/policy/harassment.htm">https://grants.nih.gov/grants/policy/harassment.htm</a>.</li>
</ul>
<ul>
<li class="Normal">For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws see <a href="https://www.hhs.gov/conscience/conscience-protections/index.html">https://www.hhs.gov/conscience/conscience-protections/index.html</a> and <a href="https://www.hhs.gov/conscience/religious-freedom/index.html">https://www.hhs.gov/conscience/religious-freedom/index.html</a>.</li>
</ul>
<p class="Normal">Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at <a href="https://www.hhs.gov/ocr/about-us/contact-us/index.html">https://www.hhs.gov/ocr/about-us/contact-us/index.html</a> or call 1-800-368-1019 or TDD 1-800-537-7697.</p>
<p class="Normal">In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206  Federal awarding agency review of risk posed by applicants.  This provision will apply to all NIH grants and cooperative agreements except fellowships. </p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165331" data-element-required="true" data-element-type="TEXT" data-section-code="AAI" tabindex="0">
						Report fraud, waste and abuse 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165331" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p class="Normal">The Office of Inspector General Hotline accepts tips from all sources about potential fraud, waste, abuse and mismanagement in Department of Health &amp; Human Services programs. The reporting individual should indicate that the fraud, waste and/or abuse concerns an SBIR/STTR grant or contract, if relevant. <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31200">Report Fraud.</a></p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165332" data-element-required="true" data-element-type="TEXT" data-section-code="AAI" tabindex="0">
						Cooperative Agreement Terms and Conditions of Award 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165332" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p>Not Applicable</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165333" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<h4>3. Data Management and Sharing</h4><p>Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.</p><ul><li>Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.2.3_sharing_research_resources.htm#Data">NIH Grants Policy Statement</a>. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described. SBIR and STTR recipients may retain the rights to data generated during the performance of an SBIR or STTR award for up to 20 years after the award date, per the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program Policy Directive. An acceptable Data Management and Sharing plan can reference and incorporate these data rights. Further information about SBIR and STTR data rights are enumerated in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_18/18.5.5_administrative_requirements.htm#Intellec:~:text=behavior%20of%20individuals.-,18.5.5.2%20Intellectual%20Property,-Rights%20to%20data">NIH GPS</a>.</li></ul>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165334" data-element-required="false" data-element-type="TEXT" data-section-code="AAI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165335" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p class="heading4">4. Reporting</p>
<p class="Normal">When multiple years are involved, recipients will be required to submit the <a href="//grants.nih.gov/grants/rppr/index.htm">Research Performance Progress Report (RPPR)</a> annually and financial statements as required in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.4.1_reporting.htm">NIH Grants Policy Statement</a>.<br/>
<br/>
NIH requires that SBIR/STTR recipients submit the following reports within 120 days of the end of the grant budget period unless the recipient is under an extension. </p>
<ul>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31162">Final RPPR</a> (requirements have recently changed - please see the <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-085.html">NOT-OD-17-085</a>)</li>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31166">Final Invention Statement and Certification (HHS 568)</a></li>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31169">Annual Invention Utilization Reports</a></li>
<li class="Normal"><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=31167">Federal Financial Report (FFR)</a></li>
<li class="Normal"><a href="https://www.sbir.gov/user/login">SBIR.gov</a></li>
</ul>
<p class="Normal">Failure to submit timely final reports may affect future funding to the organization or awards with the same PD/PI. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR 200.301.</p>
<p class="Normal">The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11170">www.fsrs.gov</a> on all subawards over the threshold. See the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82420">NIH Grants Policy Statement</a> for additional information on this reporting requirement.</p>
<p class="Normal">In accordance with the regulatory requirements provided at 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in 45 CFR Part 75 and 2 CFR Part 200   Award Term and Condition for Recipient Integrity and Performance Matters.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165352" data-element-required="true" data-element-type="TEXT" data-section-code="AAI">
<p class="Normal"><strong>Disclosure of Foreign Relationships Reporting Requirements </strong></p>
<p class="Normal">Recipients are responsible for monitoring their relationships with foreign countries of concern post-award, for any changes that may impact previous disclosures. SBCs receiving an award under the SBIR/STTR program are required to submit an updated Disclosure Form to report any of the following changes to NIH (and, CDC or, FDA, as applicable) throughout the duration of the award:</p>
<ul>
<li class="Normal">any change to a disclosure on the Disclosure Form;</li>
<li class="Normal">any material misstatement that poses a risk to national security; and</li>
<li class="Normal">any change of ownership, change to entity structure, or other substantial change in circumstances of the SBC that NIH, CDC, and FDA determine poses a risk to national security.</li>
</ul>
<p class="Normal">Regular, annual updates are required at the time of all SBIR/STTR annual, 
interim, and final Research Performance Progress Reports (RPPRs). For changes that occur between RPPR submissions,
updated Disclosure Forms are required within 30 days of any change in ownership, entity structure, covered individual, or other substantive changes in circumstance, as described above. Recipients are required to upload these updated disclosures using the Additional Materials (AM) tool in eRA Commons. </p>
<p class="Normal">If the recipient reports a covered foreign relationship that meets any of the risk criteria prohibiting funding described in this NOFO, NIH, CDC, and FDA  may deem it necessary to terminate the award for material failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.5.2_remedies_for_noncompliance_or_enforcement_actions-_suspension__termination__and_withholding_of_support.htm?Highlight=termination">Refer to NIH GPS Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support</a> for more information. Recipients are encouraged to monitor their covered foreign relationships post-award and avoid entering into relationships, both funded and unfunded, that may pose a security risk and jeopardize their ability to retain their award.</p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165336" data-element-required="false" data-element-type="TEXT" data-section-code="AAI">
<p style="margin-left:0px;"><strong>Agency Recovery Authority and Repayment of Funds</strong></p><p style="margin-left:0px;">An SBC will be required to repay all amounts received from NIH, CDC, and FDA under the award if either of the following determinations are made upon assessment of a change to their disclosure:</p><ul><li>The SBC makes a material misstatement that NIH, CDC, and FDA determine poses a risk to national security; or</li><li>There is a change in ownership, change in entity structure, or other substantial change in circumstances of the SBC that NIH, CDC, and FDA determine poses a risk to national security.</li></ul><p style="margin-left:0px;">The repayment requirements and procedures provided in <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.5.4_recovery_of_funds.htm">Section 8.5.4 Recovery of Funds</a> of the NIH GPS apply and may also be subject to additional noncompliance and enforcement actions as described in Section 8.5.2 of the GPS. Recipients are required to follow the repayment procedures provided in the <a href="https://grants.nih.gov/policy/compliance.htm">Guidance for Repayment of Grant Funds to the NIH.</a></p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165337" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<a name="_Section_VII._Agency"></a><h2 class="heading2">Section VII. Agency Contacts</h2>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165338" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<p>We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165339" data-element-required="true" data-element-type="TEXT" data-section-code="AC" tabindex="0">
						Application Submission Contacts 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165339" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<p class="Normal">eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)</p>
<p class="Normal">Finding Help Online: <a href="https://www.era.nih.gov/need-help" target="_blank" title="https://www.era.nih.gov/need-help">https://www.era.nih.gov/need-help</a>  (preferred method of contact)<br/>
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)</p>
<p class="Normal">General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)<br/>
Email: <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a> (preferred method of contact)<br/>
Telephone: 301-480-7075</p>
<p class="Normal"><a href="http://Grants.gov">Grants.gov</a> Customer Support (Questions regarding Grants.gov registration and Workspace)<br/>
Contact Center Telephone: 800-518-4726<br/>
Email: <a href="mailto:support@grants.gov">support@grants.gov</a></p>
<p class="Normal">SBA Company Registry (Questions regarding required registration at the SBA Company Registry and for technical questions or issues)<br/>
Website to Email: <a href="http://sbir.gov/feedback?type=reg">http://sbir.gov/feedback?type=reg</a></p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165340" data-element-required="true" data-element-type="TEXT" data-section-code="AC" tabindex="0">
						Scientific/Research Contact(s) 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165340" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<p>Morris Flood, DHSc<br/>National Institute on Drug Abuse (NIDA)<br/>Phone: 301-496-6144<br/>Email: <a href="mailto:morris.flood@nih.gov">morris.flood@nih.gov</a></p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165342" data-element-required="true" data-element-type="TEXT" data-section-code="AC" tabindex="0">
						Peer Review Contact(s) 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165342" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<p>Dharmendar Rathore, PhD<br/>National Institute on Drug Abuse (NIDA)<br/>Phone: 301- 402-6965<br/>Email: <a href="mailto:dharmendar.rathore@nih.gov">dharmendar.rathore@nih.gov</a> </p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165344" data-element-required="true" data-element-type="TEXT" data-section-code="AC" tabindex="0">
						Financial/Grants Management Contact(s) 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165344" data-element-required="true" data-element-type="TEXT" data-section-code="AC">
<p>Amy Connolly <br/>National Institute on Drug Abuse (NIDA) <br data-suggestion-start-after="insertion:eb4c0bee4b2c6cfab96db5184c084b24f:WALKERY_865"/>P hone: 301-827-4457 <br/>Email: <a href="mailto:connolla@mail.nih.gov">connolla@mail.nih.gov</a></p>
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165346" data-element-required="true" data-element-type="TEXT" data-section-code="OTI">
<a name="_Section_VIII._Other"></a><h2 class="heading2">Section VIII. Other Information</h2>
</div>
<div data-element-has-label="false" data-element-has-value="false" data-element-id="165347" data-element-required="false" data-element-type="TEXT" data-section-code="OTI">
</div>
<div data-element-has-label="false" data-element-has-value="true" data-element-id="165348" data-element-required="true" data-element-type="TEXT" data-section-code="OTI">
<p class="Normal">Recently issued trans-NIH <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11163">policy notices</a> may affect your application submission. A full list of policy notices published by NIH is provided in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11164">NIH Guide for Grants and Contracts</a>. All awards are subject to the terms and conditions, cost principles, and other considerations described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a>.</p>
</div>
<div class="heading4" data-element-has-value="true" data-element-id="165349" data-element-required="true" data-element-type="TEXT" data-section-code="OTI" tabindex="0">
						 Authority and Regulations 					
				</div>
<div data-element-has-label="true" data-element-has-value="true" data-element-id="165349" data-element-required="true" data-element-type="TEXT" data-section-code="OTI">
<p class="Normal">Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 45 CFR Part 75 and 2 CFR Part 200.</p>
<p class="Normal">The SBIR Program is mandated by the Small Business Innovation Development Act of 1982 (P.L. 97-219), reauthorizing legislation (P.L. 99-443) P.L. 102-564, P.L. 112-81 (SBIR/STTR Reauthorization Act of 2011), as reauthorized and extended under P.L. 114-328, Section 1834, P.L. 115-232, and P.L. 117-183. The basic design of the NIH SBIR Program is in accordance with the Small Business Administration (SBA) <a href="https://www.sbir.gov/sites/default/files/SBA_SBIR_STTR_POLICY_DIRECTIVE_OCT_2020_v2.pdf">SBIR Policy Directive</a>.</p>
<p class="Normal">The STTR Program is mandated by the Small Business Reauthorization Act of 1997 (P.L. 105-135), and reauthorizing legislation, P.L. 107-50, P.L. 112-81 (SBIR/STTR Reauthorization Act of 2011), as reauthorized and extended under P.L. 114-328, Section 1834, P.L. 115-232, and P.L. 117-183. The basic design of the NIH STTR Program is in accordance with the Small Business Administration (SBA)<a href="https://www.sbir.gov/sites/default/files/SBA_SBIR_STTR_POLICY_DIRECTIVE_OCT_2020_v2.pdf">STTR Policy Directive</a>.</p>
</div>
</div>
</div> <!-- end row -->
</div>
</body>
</div>
</div>
<div class="row">
<div class="col-xs-12">
<p>
<hr/>
<a href="/grants/guide/WeeklyIndex.cfm?09-29-23">Weekly TOC for this Announcement</a><br/>
<a href="/grants/guide/index.html">NIH Funding Opportunities and Notices</a>
<hr/>
</p></div>
</div>
<div class="row">
<div class="col-md-4"> <a href="/grants/oer.htm"><img alt="NIH Office of Extramural Research Logo" border="0" src="/images7/nih-oer-logo.jpg" usemap="#Map2"/></a>
<map id="Map2" name="Map2">
<area coords="89,17,359,39" href="http://www.nih.gov" shape="rect"/>
<area coords="91,39,286,58" href="http://grants.nih.gov/grants/oer.htm" shape="rect"/>
<area coords="3,5,78,55" href="http://grants.nih.gov/grants/oer.htm" shape="rect"/>
</map>
</div>
<div class="col-md-4">
<div style="float:left; padding: 5 5 5 70"> <a href="http://www.hhs.gov/"><img alt="Department of Health and Human Services (HHS) - Home Page" border="0" desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'" height="37" long="" src="/images7/dhhs_sm.gif" width="36"/></a></div>
<div style="padding: 5 5 5 5;">Department of Health<br/>
      and Human Services (HHS)</div>
</div>
<div class="col-md-4">
<div align="center" style="padding: 5 5 5 0"> <a href="http://www.usa.gov/"><img alt="USA.gov - Government Made Easy" border="0" desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo" long="" src="/images7/USA_Gov_logo.gif"/></a> </div>
</div>
</div>
<div class="row">
<div align="center" class="col-xs-12" style="padding: 20 5 5 5"> <span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>®</sup></span> </div>
</div>
<div class="row">
<div align="center" class="col-xs-12">
</div>
</div>
</div>
</body>
</html>